Thrombin-JMI, Thrombocoll market seen growing on surgical demand

The Business Research Company says the thrombin-JMI and Thrombocoll market is expanding as surgeons rely more on bleeding-control products and as demand rises from bleeding disorders, aging populations and more procedures worldwide. North America held the biggest share in 2025, while the report forecasts continued growth through 2026 and beyond.

Why it matters: - Thrombin-JMI and Thrombocoll are used to control bleeding during surgery, making them important for patient safety and better outcomes. - Demand for hemostatic products is rising as hospitals handle more procedures, more bleeding-risk patients and more complex operations. - The market is tied to broader shifts in surgery, trauma care and biologic wound management.

What happened: - The Business Research Company published a 2026 report on the global thrombin-JMI and Thrombocoll market. - The report says the market is seeing steady growth through 2026, with further expansion expected through 2035. - North America held the largest share of the market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available. - The full market report is also available.

The details: - The market’s growth is being supported by higher surgical procedure volumes, broader access to human thrombin products and wider adoption of wound care materials. - Improved hospital surgical infrastructure and greater clinician familiarity with hemostatic agents are also supporting demand. - The report points to growing use of topical hemostatic agents during surgery. - It also flags rising demand for rapid bleeding-control solutions and collagen-based hemostats. - Minimally invasive surgery is expanding, and that is increasing use of products that can control bleeding quickly and efficiently. - The report says stronger investment in advanced surgical products is helping the market. - Thrombin-JMI is a human thrombin-based agent that supports clot formation. - Thrombocoll is a collagen-based product that supports platelet aggregation and clotting at the wound site. - Both products are used to prevent or stop excessive bleeding during operations and invasive procedures. - Rising bleeding disorders are a major demand driver. - Bleeding risk is increasing with an aging population and more widespread use of anticoagulant medications. - Pfizer said in April 2025 that the UK had more than 11,800 patients with hemophilia A and B during 2023/24. - That patient pool points to ongoing demand for hemostatic products. - The report also cites more surgical interventions worldwide as a growth driver. - The American Society of Plastic Surgeons reported in June 2024 that minimally invasive procedures rose 7% in 2023, outpacing overall surgical growth by 2%. - Hand surgeries, including carpal tunnel, arthritis and trigger finger treatments, totaled 207,887 cases, up 2% from 2022. - The U.S. Census Bureau projected in January 2024 that the U.S. population aged 65 and older will rise from 58 million in 2022 to 82 million by 2050. - That age group’s share of the U.S. population is projected to rise from 17% to 23% over the same period.

Between the lines: - The report is framing the market as a beneficiary of structural healthcare trends, not a short-term surge. - More surgery, more elderly patients and more bleeding-risk cases all point to recurring demand for hemostatic tools. - The emphasis on minimally invasive procedures suggests the market is shifting toward products that work fast in smaller, more precise interventions. - The company’s broader reporting package, including TAM analysis and market-attractiveness scoring, signals a stronger focus on investment screening and competitive positioning.

What's next: - The report expects demand to continue rising as trauma and emergency care expand and surgical volumes grow. - Ongoing innovation in surgical sealants and advanced surgical products is likely to shape the market outlook. - Greater adoption of biologic hemostats in complex surgeries should remain a key trend. - More market intelligence updates are expected in The Business Research Company’s 2026 report series.

The bottom line: - The thrombin-JMI and Thrombocoll market is growing on durable demand for surgical bleeding control, with aging populations and higher procedure volumes doing most of the work.